Medicare Advantage and Cancer: What Every Beneficiary Must Know

When a woman receives a breast cancer diagnosis, the last thing she should have to fight is her health insurance. But for hundreds of thousands of Medicare beneficiaries enrolled in Medicare Advantage plans, that fight is exactly what happens. Prior authorization denials, narrow networks that exclude top cancer centers, and cost-sharing structures that pile up fast during active treatment have put Medicare Advantage under serious scrutiny — and for good reason. If you or someone you love is navigating cancer care on Medicare, understanding how your coverage actually works is not optional. It is urgent.

Medicare Advantage plans — also called Medicare Part C — are offered by private insurers approved by the Centers for Medicare & Medicaid Services. They must cover everything Original Medicare covers, but they are allowed to manage how and where you receive that care. That management comes in the form of provider networks, referral requirements, and prior authorization — a process where the insurer must approve a treatment or service before you receive it. For routine care, prior authorization is an inconvenience. For cancer treatment, it can be a genuine threat to timely care. Studies and patient advocacy groups have documented cases where prior authorization delayed chemotherapy, radiation, and even diagnostic imaging for weeks at a time. In cancer treatment, weeks matter.

The network issue is equally serious. Many of the country's leading cancer centers — places like MD Anderson, Memorial Sloan Kettering, Mayo Clinic, and Dana-Farber — are not in-network for most Medicare Advantage plans. If your oncologist or the specialized cancer hospital you need is out of network, you may face dramatically higher cost-sharing, or the plan may not cover that care at all outside of emergency situations. Original Medicare, by contrast, allows you to see any doctor or go to any hospital in the country that accepts Medicare — and the vast majority of oncologists and major cancer centers do. That freedom of movement is not a small thing when you are trying to access the best possible treatment.

Let's talk about what cancer treatment actually costs under Medicare Advantage. In 2025, CMS set the maximum out-of-pocket limit for Medicare Advantage plans at $8,850 for in-network services. Some plans set their limits lower, but many sit right at or near that ceiling. If your treatment requires out-of-network providers — which is common in complex cancer cases — that out-of-pocket maximum may be higher, sometimes $13,300 or more for combined in- and out-of-network costs, depending on the plan. A single hospitalization for a surgical procedure, followed by chemotherapy infusions, radiation sessions, and follow-up imaging, can push a beneficiary to that maximum within the first few months of a diagnosis. And unlike Original Medicare paired with a Medigap supplement, there is no single predictable cost structure. You are dealing with copays, coinsurance rates, and tier-based drug formularies that can shift from year to year during the Annual Enrollment Period.

Speaking of drug costs: breast cancer treatment often involves expensive oral chemotherapy agents and targeted therapies. Under Medicare Advantage drug coverage (Part D is typically bundled in), these medications may land on Tier 4 or Tier 5 of a formulary, where coinsurance — not a flat copay — applies. That means you pay a percentage of the drug's cost, not a fixed dollar amount. A targeted therapy drug that costs $10,000 per month at 25% coinsurance means $2,500 out of pocket every single month, just for that one medication, until you reach the catastrophic coverage threshold. The Inflation Reduction Act capped Medicare Part D out-of-pocket drug costs at $2,000 annually starting in 2025, which is a meaningful improvement — but that cap applies to Part D drug costs specifically and does not offset the medical cost-sharing you face for infusions, imaging, and hospital stays.

So where does hospital indemnity insurance fit into this picture? A hospital indemnity plan pays you a fixed cash benefit for each day you are hospitalized, regardless of what your primary insurance pays. For a Medicare Advantage enrollee facing a cancer-related hospitalization, that cash benefit — which might be $200, $300, or $500 per day depending on the policy — can help offset the daily copays that many Medicare Advantage plans charge for inpatient stays. Some Medicare Advantage plans charge $300 to $400 per day for the first several days of a hospital admission. A hospital indemnity plan does not replace your primary coverage, but it can meaningfully reduce the financial shock of a serious illness. Premiums for hospital indemnity plans vary widely by age and benefit level, but many beneficiaries in their late 60s and 70s can find coverage in the $50 to $150 per month range. The key is buying it before a diagnosis, not after — most plans have health underwriting requirements or waiting periods for pre-existing conditions.

For beneficiaries who are currently healthy but have a family history of breast cancer or other serious illness, this is the moment to think carefully about your coverage structure. If you are still in your Initial Enrollment Period — the seven-month window around your 65th birthday — you have guaranteed issue rights to purchase a Medigap policy without medical underwriting. That means an insurer cannot deny you or charge you more based on your health history. Once that window closes, in most states, insurers can use medical underwriting to decline your Medigap application or charge higher premiums if you have a pre-existing condition. Thirteen states have stronger protections: California, Idaho, Illinois, Kentucky, Louisiana, Maine, Maryland, Missouri, Nevada, New Jersey, New York, Oklahoma, and Oregon all have birthday rules or year-round guaranteed issue rights that give beneficiaries an annual window to switch Medigap plans without underwriting. If you live in one of these states and are currently on a Medicare Advantage plan, you may have more flexibility to switch to Original Medicare with a Medigap supplement than beneficiaries in other states.

If you are already enrolled in a Medicare Advantage plan and facing a cancer diagnosis, you are not necessarily stuck. The Annual Enrollment Period runs October 15 through December 7 each year, and changes take effect January 1. The Medicare Advantage Open Enrollment Period runs January 1 through March 31 and allows you to switch to a different Medicare Advantage plan or return to Original Medicare — though returning to Original Medicare mid-year means you may face underwriting for Medigap in most states. A Special Enrollment Period may also apply if you move, lose other coverage, or qualify under specific circumstances. Calling 1-800-MEDICARE or working with a licensed Medicare counselor through your State Health Insurance Assistance Program (SHIP) — a free, unbiased resource available in every state — can help you understand your specific options without any sales pressure.

The honest bottom line is this: Medicare Advantage plans work well for many people, particularly those who are generally healthy, stay within their network, and value the bundled benefits like dental and vision that Original Medicare does not cover. But for people with cancer, a history of cancer, or a high likelihood of needing complex specialty care, the prior authorization hurdles, network restrictions, and variable cost-sharing of Medicare Advantage can create serious financial and logistical obstacles at the worst possible time. A Medigap Plan G or Plan N paired with Original Medicare offers more predictable costs and unrestricted access to providers — and adding a hospital indemnity policy on top of that can provide an additional cash cushion for inpatient stays. That combination costs more in monthly premiums than many Medicare Advantage plans, some of which charge $0 in premiums. But when you are sitting in an oncologist's office, predictability and access are worth paying for.